Piper Sandler宣布,将生物制药公司Soleno Therapeutics的股票评级从"增持"下调至"中性"。同时,该机构将其目标股价从145美元大幅下调至53美元,显示出对公司短期前景的谨慎态度。此次评级和目标价的双重调整,可能影响市场对该股的信心。
Piper Sandler宣布,将生物制药公司Soleno Therapeutics的股票评级从"增持"下调至"中性"。同时,该机构将其目标股价从145美元大幅下调至53美元,显示出对公司短期前景的谨慎态度。此次评级和目标价的双重调整,可能影响市场对该股的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.